4Suppliers
9Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Scholar Rock Holding Corporation (SRRK) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

17Total relationships
3Distinct source URLs
7High confidence
0.788Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Scholar Rock Holding Corporation Suppliers

TickerNameConfidenceEvidence
OBDC Blue Owl Capital Corporation 90% Reciprocal relationship from OBDC graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from OBDC graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from OBDC g…
ADIMAB ADIMAB 80% Under the Adimab Agreement, as amended, we selected a number of biological targets against which Adimab used its proprietary platform technology to discover and/or optimize antibodies
DYN Dyne Therapeutics, Inc. 72% Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number…
KROS Keros Therapeutics, Inc. 72% Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirement…

Scholar Rock Holding Corporation Customers

TickerNameConfidenceEvidence
GILEAD GILEAD 90% In connection with the Collaboration Agreement, we received an upfront payment of $50 million and an equity investment of $30 million
DYN Dyne Therapeutics, Inc. 72% Reciprocal relationship from DYN graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disru…
KROS Keros Therapeutics, Inc. 72% Reciprocal relationship from KROS graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense a…
MYGN Myriad Genetics, Inc. 72% rms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a 61 Table of C…
MYGN Myriad Genetics, Inc. 72% Reciprocal relationship from MYGN graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from SRRK graph: rms and conditions of the proposed …
OBDC Blue Owl Capital Corporation 72% osses for the foreseeable future in performing our ongoing activities, as we: ● develop our commercialization capabilities to support product sales, marketing and distribution activities; ● continue …
OBDC Blue Owl Capital Corporation 72% Reciprocal relationship from OBDC graph: Reciprocal relationship from SRRK graph: osses for the foreseeable future in performing our ongoing activities, as we: ● develop our commercialization capabil…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from SRRK graph: Reciprocal relationship from SNYN…
SNYNF Sanofi 72% rms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a 61 Table of C…

Scholar Rock Holding Corporation Debt Obligations

InstrumentDescriptionConfidenceEvidence
SRRK-DEBT Debt stack $196.8M 90% Market cache reports total debt of $196.8M.
SRRK-DEBT-12742 Warrants outstanding: 7614 90% xbrl warrant detail from xbrl 2025-12-31.
SRRK-DEBT-12743 Xbrl Convertible 90% xbrl convertible detail from xbrl 2018-12-31.

Scholar Rock Holding Corporation Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Scholar Rock Holding Corporation.

Scholar Rock Holding Corporation Ownership

HolderNameConfidenceEvidence
SRRK-OWNER-FMR-LLC FMR LLC 90% 13F overlay lists FMR LLC as top holder; 283 tracked holders.

Scholar Rock Holding Corporation Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
BBIO BridgeBio Pharma, Inc. 100.00 2
ATOS Atossa Therapeutics, Inc. 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
HTGC Hercules Capital, Inc. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
DYN Dyne Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
ANL Adlai Nortye Ltd. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
BNBX BNB Plus Corp. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
AZN AstraZeneca PLC 100.00 2
CPRX Catalyst Pharmaceuticals, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
BNTC Benitec Biopharma Inc. 100.00 2
🔐
SRRK
Unlock SRRK Supply Chain Data
Verified relationships include:
OBDCBlue Owl Capital CorporationSupplier90%
ADIMABADIMABSupplier80%
GILEADGILEADCustomer90%
DYNDyne Therapeutics, Inc.Customer72%
+13 more relationships locked
Subscribe, View plans →